Sunesis Pharmaceuticals (SNSS)

[barefootrunner]

Yes. The AML data was very solid...better than the data presented at ASH last December.

I know the Ovarian Cancer data doesn't look great on the surface, but keep in mind the following:

1. Ovarian cancer is one of the hardest cancers to treat and one of the fastest killers.

2. They have a clinical science symposium for the presentation of the OC data. The clinical science symposium is one of the most prestigious venues at ASCO.

3. The abstracts were submitted over 4 months ago. It is quite possible that the data has changed/improved since that time via the exhaustive statistical analyses that go on behind the scenes with clinical data.

4. Part of the patient population in the trial had failed prior treatment with pegylated liposomal doxorubicin (PLD, Doxil). This is another group that could benefit from Voreloxin for OC.

Agreed the pps is frustrating, but I am holding until the final results unless the pps takes a sudden, dramatic movement south of .75, which does not look likely.

Hope this helps!